Last reviewed 2026-04-23 · How we verify

Investigational Drug, MW-III

Skingenix, Inc. · Phase 2 active Small molecule

Investigational Drug, MW-III is a Small molecule drug developed by Skingenix, Inc.. It is currently in Phase 2 development.

At a glance

Generic name	Investigational Drug, MW-III
Sponsor	Skingenix, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Investigational Drug, MW-III CI brief — competitive landscape report
Investigational Drug, MW-III updates RSS · CI watch RSS
Skingenix, Inc. portfolio CI

Frequently asked questions about Investigational Drug, MW-III

What is Investigational Drug, MW-III?

Investigational Drug, MW-III is a Small molecule drug developed by Skingenix, Inc..

Who makes Investigational Drug, MW-III?

Investigational Drug, MW-III is developed by Skingenix, Inc. (see full Skingenix, Inc. pipeline at /company/skingenix-inc).

What development phase is Investigational Drug, MW-III in?

Investigational Drug, MW-III is in Phase 2.

Manufacturer: Skingenix, Inc. — full pipeline
Compare: Investigational Drug, MW-III vs similar drugs
Pricing: Investigational Drug, MW-III cost, discount & access